University of Chicago-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2024

  1. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

    ESMO Open, Vol. 9, Núm. 6

2023

  1. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

    Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 181-193